3种用药方案治疗脑动脉硬化症的成本-效果分析  

Three Therapeutic Schemes for Cerebral Arteriosclerosis:Cost-Effectiveness Analysis

作　　者：苏伟琴 杨国才 

机构地区：[1]广东湛江市第二人民医院,湛江市524003

出　　处：《中国药房》2008年第20期1521-1522,共2页China Pharmacy

摘　　要：目的:比较3种用药方案治疗脑动脉硬化症的成本-效果。方法:191例脑动脉硬化症患者随机分为3组:脑络通胶囊+银杏叶胶囊(A组)、脑安胶囊(B组)、脑心通胶囊(C组),3组均同时加用阿司匹林肠溶片,用药时间均为90d,运用药物经济学原理进行成本-效果分析。结果:A、B、C组总有效率分别为84.8%、86.7%、93.8%,3组疗效无显著性差异(P>0.05);A、B、C组成本分别为459.00、481.68、789.48元,A组与C组、B组与C组的成本比较有显著性差异(P<0.01),A、B组的成本比较无显著性差异(P>0.05)。结论:A组方案较经济,但A、B组的成本差别不大。OBJECTIVE： To compare the cost- effectiveness among 3 therapeutic schemes in treating cerebral arteriosclerosis. METHODS： 191 patients with cerebral arteriosclerosis were randomly assigned to receive Naoluotong Capsules plus Ginkgo Biloba Extract and Aspirin Enteric - coated Tablets （Group A）, Naoan Capsule plus Aspirin Enteric coated Tablets （Group B）, or Cerecarton Capsules plus Aspirin Enteric-coated Tablets （Group C）. The course of treatment was 90 days for all the 3 groups. The cost-effectiveness analysis was performed using the theory of pharmacoeconomics. RESULTS： In Group A, B and C, the total effective rates were 84.8%, 86.7% and 93.8%, respectively, showing no significant differences in clinical efficacy among the 3 groups（P 〉0.05） ; the costs were 459.00 yuan, 481.68 yuan and 789.48 yuan, respectively, showing significant differences between Group A and Group C or between Group B and Group C （P〈0.01）, while there was no significant difference between Group A and Group B（P 〉0.05）. CONCLUSION： Group A is preferable in terms of cost-effectiveness, while there was no significant difference between Group A and Group B in cost.

关 键 词：脑络通胶囊 银杏叶胶囊 脑安胶囊 脑心通胶囊 脑动脉硬化症 成本-效果分析 

分 类 号：R972.6[医药卫生—药品] R956[医药卫生—药学]